Lotiglipron

Lotiglipron
Identifiers
  • 2-{[4-[(2S)-2-(5-chloropyridin-2-yl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl]methyl}-3-{[(2S)-oxetan-2-yl]methyl}benzimidazole-5-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC31H31ClN4O5
Molar mass575.06 g·mol−1
3D model (JSmol)
  • C[C@]1(c2ccc(Cl)cn2)Oc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)c2O1
  • InChI=1S/C31H31ClN4O5/c1-31(27-8-6-21(32)16-33-27)40-26-4-2-3-23(29(26)41-31)19-9-12-35(13-10-19)18-28-34-24-7-5-20(30(37)38)15-25(24)36(28)17-22-11-14-39-22/h2-8,15-16,19,22H,9-14,17-18H2,1H3,(H,37,38)/t22-,31-/m0/s1
  • Key:SVPYZAJTWFQTSM-UGDMGKLASA-N

Lotiglipron is a non-peptide GLP-1 receptor agonist which was under development by Pfizer as a weight loss drug. However, it was withdrawn from development in June 2023, after early stage clinical trials showed elevated liver enzymes which could indicate potential for liver toxicity.

See also

References

  1. ↑ US 10676465, Aspnes GE, et al., "GLP-1 receptor agonists and uses thereof", issued 9 June 2020, assigned to Pfizer Inc
  2. ↑ Griffin M (26 June 2023). "Pfizer Shares Drop After It Halts Development of Obesity Drug Due to Safety Concerns". Time.